News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,019 Results
Type
Article (8027)
Company Profile (141)
Press Release (477850)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166752)
Career Advice (304)
Deals (25738)
Drug Delivery (7)
Drug Development (52882)
Employer Resources (14)
FDA (9760)
Job Trends (8573)
News (238209)
Policy (17898)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33141)
ALS (108)
Alzheimer's disease (989)
Antibody-drug conjugate (ADC) (284)
Approvals (10394)
Artificial intelligence (333)
ASCO (159)
Autoimmune disease (220)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6952)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (1)
Bladder cancer (139)
Brain cancer (31)
Breast cancer (519)
Cancer (3759)
Cardiovascular disease (226)
Career advice (242)
Career pathing (1)
CAR-T (178)
CDC (1)
CDMO (15)
Celiac Disease (1)
Cell therapy (486)
Cervical cancer (35)
Clinical research (47968)
Collaboration (1278)
Commercialization (3)
Compensation (1533)
Complete response letters (34)
COVID-19 (759)
CRISPR (64)
C-suite (802)
Cystic fibrosis (87)
Data (5846)
Denatured (4)
Depression (106)
Dermatology (67)
Diabetes (354)
Diagnostics (4218)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73745)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88086)
Executive appointments (713)
FDA (12473)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (945)
Gene editing (126)
Generative AI (11)
Gene therapy (332)
GLP-1 (295)
Government (944)
Grass and pollen (2)
Guidances (281)
Healthcare (9362)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (68)
Immunology and inflammation (106)
Immuno-oncology (61)
Indications (162)
Infectious disease (951)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (261)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (232)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5194)
Licensing (18)
Liver cancer (45)
Longevity (19)
Lung cancer (542)
Lymphoma (257)
Machine learning (29)
Management (3)
Manufacturing (563)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8671)
Medtech (8830)
Mergers & acquisitions (14409)
Metabolic disorders (726)
mRNA (62)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (227)
Neuropsychiatric disorders (40)
Neuroscience (1873)
NextGen: Class of 2026 (3148)
Non-profit (843)
Obesity (231)
Opinion (10)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (206)
Parkinson's disease (206)
Partnered (12)
Patents (497)
Patient recruitment (530)
Patient selection (2)
Peanut (32)
People (41356)
Peptides (2)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15506)
Phase 2 (21430)
Phase 3 (14436)
Pipeline (7683)
Policy (18)
Postmarket research (1559)
Preclinical (6550)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (195)
Rare diseases (588)
Real estate (3021)
Recruiting (6)
Regenerative medicine (2)
Regulatory (14925)
Reports (23)
Research institute (583)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (163)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2023)
Stomach cancer (3)
Supply chain (51)
Vaccines (320)
Venture capital (17)
Weight loss (75)
Women's health (88)
Date
Today (1)
Last 7 days (284)
Last 30 days (1354)
Last 365 days (19012)
2026 (13618)
2025 (19251)
2024 (22987)
2023 (26540)
2022 (34578)
2021 (37169)
2020 (33469)
2019 (23256)
2018 (17462)
2017 (18766)
2016 (17921)
2015 (24250)
2014 (21677)
2013 (18137)
2012 (20223)
2011 (20442)
2010 (20318)
Location
Africa (229)
Alabama (77)
Alaska (2)
Arizona (310)
Arkansas (11)
Asia (17960)
Australia (2107)
California (12347)
Canada (3237)
China (544)
Colorado (496)
Connecticut (427)
Delaware (214)
Europe (24693)
Florida (1854)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (726)
India (52)
Indiana (323)
Iowa (16)
Japan (423)
Kansas (103)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1231)
Massachusetts (8100)
Michigan (314)
Minnesota (572)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (122)
New Hampshire (60)
New Jersey (2691)
New Mexico (12)
New York (2896)
North Carolina (1316)
North Dakota (4)
Northern California (6210)
Ohio (293)
Oklahoma (14)
Oregon (16)
Pennsylvania (2295)
Puerto Rico (21)
Rhode Island (30)
South America (406)
South Carolina (78)
South Dakota (1)
Southern California (5138)
Tennessee (125)
Texas (2004)
United States (40018)
Utah (372)
Vermont (1)
Virginia (159)
Washington D.C. (38)
Washington State (955)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
486,019 Results for "amyris inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dr. Sunil Chandran Rejoins Amyris as Chief Technology Officer to Meet Growing Customer Demand for Innovative and Renewable Biological Chemistry
September 3, 2025
·
2 min read
Business
Amyris, Inc. Reports First Quarter 2023 Financial Results
Amyris, Inc. announced financial results for the first quarter ended March 31, 2023.
May 9, 2023
·
16 min read
Deals
Amyris Announces Operational and Financial Restructuring to Advance Strategic Transformation
Amyris, Inc. announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.
August 9, 2023
·
7 min read
Biotech Bay
Amyris Successfully Advances Strategic Transaction
Amyris, Inc. announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris’ ingredients.
December 27, 2022
·
4 min read
Business
Amyris Announces CEO Transition and Global Reduction in Force
Amyris, Inc. announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately.
June 26, 2023
·
4 min read
Business
AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE
Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.
May 19, 2023
·
5 min read
Business
Amyris Reports Q1 2023 Revenue
Amyris, Inc., a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, provided an update on first quarter revenue.
April 24, 2023
·
3 min read
Biotech Bay
Amyris Closes Strategic Transaction With Givaudan
Amyris, Inc. announced that it has completed the previously announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance® Squalane, the highest performant emollient, Neossance® Hemisqualane, the plant-based silicone alternative, and CleanScreen™, the sustainable sun protector.
April 5, 2023
·
4 min read
Business
AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the fourth quarter and full year ended December 31, 2022.
March 15, 2023
·
21 min read
Business
Amyris, Inc. Reports Third Quarter 2022 Financial Results
Amyris, Inc., a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, announced financial results for the third quarter ended September 30, 2022.
November 8, 2022
·
22 min read
1 of 48,602
Next
